Genre
Pre-printDate
2020-09-12Author
Patel, MaulinDominguez Castillo, Eduardo

Sacher, Daniel

Desai, Parag
Chandar, Ashwin
Bromberg, Michael
Caricchio, Roberto

Criner, Gerard J.
Group
COVID-19 Research Group (Temple University)Department
Thoracic Medicine and SurgeryHematology and Oncology
Rheumatology
Permanent link to this record
http://hdl.handle.net/20.500.12613/4153
Metadata
Show full item recordDOI
https://doi.org/10.1016/j.chest.2020.09.077Abstract
Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.Citation to related work
ElsevierHas part
ChestADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/4135